Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the initiation of a Phase I trial with the first doses administered for TQA3038, a small interfering RNA (siRNA) drug targeting the hepatitis B virus (HBV) for the treatment of chronic hepatitis B (CHB). The trial is currently recruiting healthy adults to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of the molecule.
TQA3038 is a GalNAc-conjugated siRNA drug designed to accumulate in the liver, where it can effectively degrade targeted RNA, inhibit the translation of relevant proteins, and block HBV replication. Sino Biopharmaceutical aims for TQA3038 to serve as the foundation of a functional cure in clinical settings, defined as sustained clearance of HBsAg and HBV DNA in the blood serum following a limited treatment period. Globally, there are approximately 290 million individuals suffering from HBV, with around 86 million of those in China. Current treatment options, including nucleoside analogues (NAs) and interferon, often fail to achieve a durable cure for the condition.- Flcube.com
